HLP005
Serotonergic psychedelic
From Wikipedia, the free encyclopedia
HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of psychiatric disorders and neuroinflammation.[2][3][1]
| Clinical data | |
|---|---|
| Other names | HLP005; HLP-005; CYB005; CYB-005; Deuterated phenethylamine; Deuterated phenethylamine derivative |
| Drug class | Serotonin receptor agonist; Serotonergic psychedelic; Antiinflammatory drug[1] |
Interactions
Pharmacology
Pharmacodynamics
HLP005 acts as a serotonin receptor agonist and is a serotonergic psychedelic.[2][1] In addition, HLP005 may also inhibit serotonin and dopamine reuptake.[1]
Chemistry
It is a phenethylamine derivative and a deuterated compound.[2][3][1] The exact chemical structure of HLP005 does not yet seem to have been disclosed.[2][1] However, it appears to be closely related to CYB210010, which itself is non-deuterated.[4][5][6] In addition, HLP005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.[2][4][7]
Research
As of October 2024, HLP005 is in the research or preclinical stage of development.[2][3] It has been in this developmental stage since at least 2022.[1] The drug is under development by Helus Pharma (formerly Cybin).[2][3][1] Other related drugs include the deuterated tryptamines CYB003 and CYB004.[1][8]